7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow Recurrent Glioblastoma Multiforme: new trials by email Literature Review of Recurrent Glioblastoma Multiforme trials Research Report on Recurrent Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Vorinostat, Bevacizumab - Recurrent Glioblastoma Multiforme, Malignant Glioma | Phase 2 | Completed | Duke University | 48 | 2013-01-01 | 2017-03-06 |
| Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Stereotactic hypofractionated RT 5x5Gy, Stereotactic hypofractionated RT 5x7Gy - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Andre Tsin Chih Chen | 40 | 2011-10-01 | 2024-12-09 |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme temozolomide and bevacizumab - Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | Phase 2 | Completed | Center for Neurosciences, Tucson | 30 | 2009-04-01 | 2017-03-30 |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Sorafenib and Temozolomide - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Duke University | 32 | 2007-09-01 | 2013-06-24 |
| Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Panzem NCD, Temozolomide - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 15 | 2007-04-01 | 2008-11-25 |
| Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Panzem Nanocrystal Colloidal Dispersion - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 27 | 2006-01-01 | 2008-12-10 |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors TP-38, TP38 - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 56 | 2003-10-01 | 2012-01-20 |
Glioblastoma (7) · Glioma (4) · Brain Neoplasms (3) · Gliosarcoma (2)
Astrocytoma (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neoplasms, Neuroepithelial (7) · Neuroectodermal Tumors (7) · Brain Diseases (3) · Central Nervous System Diseases (3) · Central Nervous System Neoplasms (3) · Glioma (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3)
Temozolomide (3) · 2-Methoxyestradiol (2) · Bevacizumab (2) · Immunotoxins (1) · Sorafenib (1) · Vorinostat (1) · transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) (1)
CASI pharmaceuticals, Inc. (2) · Duke University (2) · Andre Tsin Chih Chen (1) · Center for Neurosciences, Tucson (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (5) · Brazil (1)
Andre T Chen, M.D. / PhD (1) · Annick Desjardins, MD (1) · David A Reardon, MD (1) · David A. Reardon, M.D. (1) · Katherine Peters, MD, PhD (1) · Michael A. Badurddoja, MD (1)